Wanbang Biopharmaceuticals Co. Ltd

Wanbang Biopharmaceuticals Co. Ltd is a prominent player in the biotechnology, manufacturing, and pharmaceutical industries, with a history dating back to its establishment in 1981. It operates as a core member of Shanghai Fosun Pharmaceutical (Group) Co., Ltd and has made significant strides in advancing pharmaceutical research and production using advanced gene cell engineering and comprehensive pharmaceutical services.

The company has garnered attention due to its substantial investment in research and development, allocating approximately 10% of its sales revenue for this purpose. Wanbang Biopharma boasts an R&D team consisting of over 200 full-time staff, with a majority holding master's and doctoral degrees. Moreover, it consistently applies for numerous national patents annually and launches several new products into the market.

Wanbang Biopharma's influence extends through 17 subsidiaries and 10 manufacturing sites across China. Notably, it recently invested nearly 600 million RMB to construct a cGMP standard biological product workshop and FPF joint workshop, aligning with European and American pharmaceutical management concepts. These facilities incorporate top-of-the-line production and analysis equipment.

The most recent funding round for Wanbang Biopharmaceuticals occurred on 01 July 2001, with Good Capital Group participating as investors, further cementing its trajectory as a key player in the biopharmaceutical sector.